Toxicity Testing For Topical Drugs, Sunscreens Included, On Tap In US FDA Workshop
Executive Summary
While FDA does not identify specific product types on the agenda for its public workshop on approaches in skin toxicity testing for topical drug products, advocacy and trade groups anticipate sunscreen ingredient testing could be among the discussion topics. Product expansions have been stifled by regulatory concerns, drawing particular attention from the public health community.
You may also be interested in...
US FDA's Sunscreen Progress Gets Dim Review From Congressional Appropriators
House and Senate appropriators' take note that US FDA has not approved an additional OTC sunscreen ingredient since the 2014 passage of the Sunscreen Innovation Act.
Exclusivity Period Allowed By OTC Monograph Reform Likely Up To Conference Committee
Next step for OTC monograph reform legislation is Senate consideration; market exclusivity periods are likely focus of House/Senate conference. Separate bill to allow consumers to use health savings accounts to buy OTC drugs without a doctor's prescription clears House Ways and Means panel.
Feminine Cleanser Marketing Never Without Challenges; Now The Category Has FDA’s Attention
FDA is investigating use of certain ingredients in feminine cleansing and hygiene products, according to its fiscal 2019 budget justification. The agency’s work could draw unfavorable attention to a category that already comes under fire regularly for alleged body shaming and disproportionate ill effects on women of color, among other accusations.